Clause 5.1

What this clause covers

Companies must maintain high standards at all times. This is a broad standards clause invoked when conduct falls below what is expected of a responsible pharmaceutical company, even where no specific promotional clause is breached. Applies to all interactions, not just promotion.

PMCPA Cases — Clause 5.1

113 cases

📅 8 Mar 2026 · Novo Nordisk

Novo Nordisk breached Clause 5.1 after listing an 0845 number for side-effect reporting on Saxenda patient website without call-cost information (AUTH/3545/7/21)

Clause 5.1

↗

📅 8 Mar 2026 · Roche

Roche voluntary admission: Gazyvaro nurse leavepiece contained a 10x dosing typo (AUTH/3568/10/21)

Clause 2 Clause 5.1 Clause 6.1

↗

📅 8 Mar 2026 · Daiichi-Sankyo UK

Daiichi-Sankyo: ‘Add on’ cholesterol ad misleading due to simvastatin contraindication buried in footnote (AUTH/3542/7/21)

Clause 2 Clause 5.1 Clause 6.1 Clause 6.2

↗

🔒

See all 113 cases for Clause 5.1

Case Library members get full access to every PMCPA ruling, searchable by clause, company, outcome, and sanction.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

Already a member? Sign in

PMCPA Cases — Clause 5.1

Novo Nordisk breached Clause 5.1 after listing an 0845 number for side-effect reporting on Saxenda patient website without call-cost information (AUTH/3545/7/21)

Roche voluntary admission: Gazyvaro nurse leavepiece contained a 10x dosing typo (AUTH/3568/10/21)

Daiichi-Sankyo: ‘Add on’ cholesterol ad misleading due to simvastatin contraindication buried in footnote (AUTH/3542/7/21)

See all 113 cases for Clause 5.1

📰 Weekly PMCPA Case Breakdown